179 results about "CARCINOMA BREAST" patented technology

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 mug agent / mumole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The invention relates to a marine bacillus and its polypeptide with antitumor activity. The strain is preserved at China Center for Type Culture Collection in Wuhan, and its preservation number is CCTCC M 2013063. A novel marine bacillus polypeptide with anti-tumor activity is obtained from a fermentation product of the strain. By means of an MTT method, the invention finds that the polypeptide has an obvious proliferation inhibition effect on human hepatoma carcinoma cell BEL-7402, human breast cancer cell MCF-7, human glioma cell U251, human non-small-cell lung cancer cell A549 and other tumor cells, has relatively small cytotoxicity on human fibroblast HFL1, and can be applied in drugs treating human liver cancer, gliomas, lung cancer and breast cancer.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

The invention discloses a detection primer combination and a kit for HER2 (human epidermal growth factor receptor 2) gene amplification. The detection primer combination comprises an HER2 primer combination and a GAPDH reference primer combination; each combination comprises upstream and downstream amplification primers of a target gene of the combination and a Taqman fluorescent probe. The kit comprises the detection primer combination, a positive quality control and a negative quality control. By using the detection primer combination and the kit, whether the HER2 gene in patients with breast carcinoma is amplified or not can be detected quickly and simply; compared with the FISH (fluorescent in situ hybridization) method, a method using the detection primer combination and the kit is high in detection sensitivity, low time consumption, generally 1.5 to 2 hours for acquiring reaction results, low in cost, low in false positive ratio, and suitable for large-scale clinical development; thus, quick, effective and accurate detection is achieved for HER2 gene amplification, and timely disease treatment and treatment effect monitoring are guaranteed.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.

A method for selectively heating cancerous conditions of the breast including invasive ductal carcinoma and invasive glandular lobular carcinoma, and pre-cancerous conditions of the breast including ductal carcinoma in-situ, lobular carcinoma in-situ, and intraductal hyperplasia, as well as benign lesions (any localized pathological change in the breast tissue) such as fibroadenomas and cysts by irradiation of the breast tissue with adaptive phased array focused microwave energy is introduced. Microwave energy provides preferential heating of high-water content breast tissues such as carcinomas, fibroadenomas, and cysts compared to the surrounding lower-water content normal breast tissues. To focus the microwave energy in the breast, the patient's breast can be compressed and a single electric-field probe, inserted in the central portion of the breast, or two noninvasive electric-field probes on opposite sides of the breast skin, can be used to measure a feedback signal to adjust the microwave phase delivered to waveguide applicators on opposite sides of the compressed breast tissue. The initial microwave power delivered to the microwave applicators is set to a desired value that is known to produce a desired increase in temperature in breast tumors. Temperature feedback sensors are used to measure skin temperatures during treatment to adjust the microwave power delivered to the waveguide applicators to avoid overheating the skin. The microwave energy delivered to the waveguide applicators is monitored in real time during treatment, and the treatment is completed when a desired total microwave energy dose has been administered. By heating and destroying the breast lesion sufficiently, lesions can be reduced in size and surrounding normal breast tissues are spared so that surgical mastectomy can be replaced with surgical lumpectomy or the lesions can be completely destroyed so that surgical mastectomy or lumpectomy is avoided.

The invention discloses a molecular marker for diagnosing breast cancer, which is used for detecting expression of the thioredoxin (TRX) and the thioredoxin binding protein 2 (TRX-binding protein-2, TBP-2) in surrounding normal breast tissue and mass tissue. A protein immunoblot experiment is used for detecting the expression amount of the thioredoxin and the thioredoxin binding protein 2; in breast mass tissue, the expression of the thioredoxin is increased and the expression of the thioredoxin binding protein 2 is decreased; as significant difference exists between the breast mass tissue and the normal breast tissue, the thioredoxin and the thioredoxin binding protein 2 can be used as a new molecular marker of breast cancer and used for the clinical diagnosis of breast cancer.

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.

The invention relates to a method for diagnosing cancers by quantitively detecting 1 tumor specific related genes and products thereof in a tumor product such as mRNA or protein as well as application thereof to preparing a diagnosis kit. In the invention, an identification method and a kit of tumor specific related genes and products thereof can be effectively applied to the sensitive diagnosis and relative treatment for the cancers.

The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg / kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and / or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma.

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast, intestine and colon, lung, ovarian or prostate cancer and non-cancerous disease states in breast, intestine and colon, lung, ovarian or prostate, identifying breast, intestine and colon, lung, ovarian or prostate tissue, monitoring and identifying and / or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast, intestine and colon, lung, ovarian or prostate tissue for treatment and research.

The invention relates to a method for preparing Lonicera macranthoides saponin and its application in treating liver cancer, breast cancer and carvical carcinoma. Said method comprises following steps: extracting Lonicera macranthoides and bud with ethanol, decoloring with active carbon, grading in macroreticular resinous column or polyamide column, washing with ethanol, basic hydrolyzing, decoloring with active carbon for the second time, crystallizing and getting said product. The invention is characterized by high productivity and purity of effective component, which is about 98%, and is especially for large- scale production. The effective dosage of Lonicera macranthoides saponin is toxic to external cancer cell, and inhibitive to mouse liver cancer H22, mouse S180 cancer and Lewis lung cancer.

The invention belongs to the field of medicines, and relates to an application of a method for degrading all carbohydrate chains in the blood to be monosaccharide and detecting the monosaccharide in cancer detection. A sample in the method for degrading the blood to obtain the monosaccharide and detecting the monosaccharide is the blood, and the cancer includes lung cancer, gastric cancer, ovarian cancer, penis cancer, esophagus cancer, oral cancer, biliary duct cancer, breast cancer, adenocarcinoma perampullaire, rectal cancer and bladder cancer. The method has the characteristics of simplicity and easiness in operation steps, easiness in popularization, short detection time, low requirement on the instrument, low detection cost, less consumption of blood and the like. The result displays that based on the content of eight monosaccharides in the blood, not only can a normal person and a cancer patient be distinguished, but also different cancers can be distinguished. The method for simplifying glycomics knowledge and applying in the detection of the biomarker of blood is first created in the world.

Aspects of the present invention provide compositions and methods for prognosis of, and / or predicting the estrogen treatment outcome of breast cell proliferative disorder patients, and in particular of patients with breast carcinoma. In preferred embodiments, this is achieved, at least in part, by determining the expression level of PITX2, and / or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. Additional aspects of the invention provide novel sequences, oligomers (e.g., oligonucleotides or peptide nucleic acid (PNA)-oligomers), and antibodies, which have substantial utility in the described inventive methods and compositions.

The present invention is based, in part, on the discovery that GOLPH3 plays a role in cancer, including lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring cancer, e.g., lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma.

The invention discloses a breast tumor prognosis biomarker LncRNA detection method and clinical application thereof, provides a group of new LncRNA in sequence shown as SEQ ID No1, SEQ ID No2, SEQ ID No3, SEQ ID No4 and SEQ ID No5 and relates to a method of taking specific LncRNA in samples (tissues, serum, urine, body fluid and the like) of patients suffering from breast tumors and corresponding juxtacancerous samples or normal samples as detection markers and biomarkers for prognostic auxiliary detection of breast tumors, related kits and a high-throughput sequencing and screening method. In-vitro diagnosis and judgment of canceration and process of breast tumors are realized by identification of differences of LncRNA expression quantity in the breast tumor samples and the corresponding juxtacancerous samples or normal samples. The invention further provides usage of the LncRNA as a breast tumor marker and probes and primers for LncRNA detection.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

Oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with either overexpression of Apo-B100, expression of mutated Apo-B100 or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

The invention relates to a kueide mycin which is a novel derivative of geldanamycin. According to the anticancer activity experiment, kueide mycin has in both vitro and vivo antitumor activities. The kueide mycin has the in vitro activity characteristics of inhibiting tumor cell proliferation, inducing the tumor cell apoptosis, reducing related target proteins of Hsp 90 in the tumor cells, as well as inhibiting the tumor cell migration, and has in vivo antitumor activity characteristics of notably reducing poisonousness compared to the geldanamycin. The kueide mycin can obviously inhibit the growth of solid tumor of a nude mouse model of Human breast carcinoma xenografts after being injected in a peritoneal cavity and is expected to be developed into a clinical effective antitumor drug.

The invention discloses a medicament for treating epithelium tumor which comprises the following constituents (by weight percentage): curcumin 0.1-90%, catechin 0.1-90%, quercetin 0.1-90%, OPC 0.1-90%, ginseng saponin 0.1-90% and polysaccharides 0.1-90%.

The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.